# Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)

> **NCT03472274** · PHASE2 · COMPLETED · sponsor: **Fundacion CRIS de Investigación para Vencer el Cáncer** · enrollment: 101 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab
- **DRUG:** Cisplatin-based neoadjuvant chemotherapy

## Key facts

- **NCT ID:** NCT03472274
- **Lead sponsor:** Fundacion CRIS de Investigación para Vencer el Cáncer
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-25
- **Primary completion:** 2021-04-30
- **Final completion:** 2023-04-12
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2023-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03472274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03472274, "Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03472274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*